Abstract
A broad family of nucleoside analogues are able to inhibit the infectivity and replication of several HIV-1 strains in vitro.1,2 The most popular of these compounds, AZT (3’-azido-3’-deoxythymidine), has been approved in the U.S.A. as a prescription drug since 1987. Although AZT reduces morbidity and mortality associated with severe HIV infection, several toxic effects have limited its long-term administration. 2’,3’-Dideoxycytidine (ddCyd) was subsequently tested clinically3 as potential therapeutic agent. Again ddCyd has shown immunological and virologic improvement in AIDS patients but most individuals developed dose-limiting toxic effects. The same applies to 2’,3’-dideoxyinosine (ddl).4,5 In an attempt to overcome the problem of nucleoside analogue toxicity and to increase their half-life in circulation we have previously synthesized 2’,3’-dideoxycytidine-5’-phosphate (ddCMP) as a prodrug, encapsulated it in human erythrocytes by a procedure of hypotonic hemolysis and resealing, and found that it is dephosphorylated by endogenous pyrimidine nucleotidases and subsequently released by the cells as ddCyd.6 By this way the prodrug is confined within the erythrocytes so that its toxicity is strongly reduced and its delivery is slow enough to ensure a long-lasting plasma concentration.? Unfortunately this drug delivery system does not solve several other problems of nucleoside analogue efficacy. In fact, to be pharmacologically useful dideoxynucleosides must be phosphorylated to 5’-triphosphate by cellular kinases.1,2 Different cell types within the same species have different abilities to phosphorylate these compounds, furthermore, other drugs can potentiate or reduce the activity of these nucleoside analogues by interfering with their metabolism directly or indirectly.8 Macrophages, which are known to be important hosts for HIV-1 with a key role in the propagation of virus as well as in the pathogenesis of AIDS, has low phosphorylating activities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
H. Mitsuya, R. Yarchoan and S. Broder, Molecular targets for AIDS therapy, Science, 249:1533 (1991).
H. Mitsuya, R. Yarchoan, S. Kagayama and S. Broder, Targeted therapy of human immunodeficiency virus-related disease, FASEB J., 5:2369 (1991).
R. Yarchoan, C.F. Perno, R.V. Thomas, R.W. Kleckeer, J.P. Allain, J. Wills, N. McAtre, M.A. Fischi, R. Dubinski, M.C. McNeely, H. Mitsuya, J.M. Pluda, T.J. Lawley, M. Leuther, B. Safai, J.M. Collins, C.E. Myers and S. Broder, Phase I studies of 2’,3’-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT), Lancet, 1:76 (1988).
T.P. Cooley, L.M. Kunches, C.A. Saunders, J.K. Ritter, C.J. Parkins, C. McLaren, R.P. McCaffrey and H.A. Liebman, Once-daily administration of 2’,3’dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial, N. Engl. J. Med., 322:1340 (1990).
J.S. Lambert, M. Seidlin, R.C. Reichman, C.S. Plank, M. Laverty, G.D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F.T. Valentine and R. Dolin, 2’,3’-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial, N. Engl. J. Med., 322:1338 (1990).
M. Magnani, M. Bianchi, L. Rossi and V. Stocchi, Human red blood cells as bioreactors for the release of 2’,3’-dideoxycytidine an inhibitor of HIV infectivity, Biochem. Biophys. Research Commun., 164:446 (1989).
F. Solimano, G.I. Bischi, M. Bianchi, L. Rossi and M. Magnani, A nonlinear three compartment model for the administration of 2’,3’-dideoxycytidine by using red blood cell as bioreactors, Bull. Math. Biol. 52:785 (1990).
J. Szebeni, S.M. Wahl, M. Popovic, L.M. Wahl, S. Gartner, R.L. Fine, U. Skaleric, R.M. Fiedman and J.M. Weinstein, Dipyridamole potentiates the inhibition by 3’azido-3’-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages, Proc. Natl. Acad. Sci. U.S.A. 86:3842 (1989).
D.E. Mosier, R.A. Yetter and H.C. Morse III, Functional T lymphocytes are required for a murine retrovirus induced immunnodeficiency disease (MAIDS), J. Exp. Med. 165:1734 (1987).
F. Turrini, P. Arese, J. Yuan, P. Low, Clustering of integral membrane proteins of the human erythrocyte membrane stimulates autologous IgG binding, complement deposition and phagocytosis, J. Biol. Chem. in press.
P. Jolicoeur, Murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis, FASEB J. 5:2398 (1991).
J. Balzarini, R. Panwels, M. Baba, P. Herdewijn, E. De Clerq, S. Broder and D.G. Johns, The in vitro and in vivo anti-retrovirus activity and intracellular metabolism of 3’-azido-2’,3’-dideoxythymidine and 2’,3’-dideoxycytidine are highly dependent on the cell species, Biochem. Pharmacol. 37:897 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Magnani, M. et al. (1992). Red Blood Cells as Advanced Drug Delivery Systems for Antiviral Nucleoside Analogues. In: Magnani, M., DeLoach, J.R. (eds) The Use of Resealed Erythrocytes as Carriers and Bioreactors. Advances in Experimental Medicine and Biology, vol 326. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3030-5_30
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3030-5_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6321-7
Online ISBN: 978-1-4615-3030-5
eBook Packages: Springer Book Archive